Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

ForteBio introduces new Octet QK(e) instrumentation system

ForteBio®, Inc., a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced the launch of its new Octet QK(e) instrumentation system. The new system, the next generation of the company's initial eight-channel Octet QK instrument, provides significantly increased sensitivity, enabling analysis of small proteins and peptides. Additionally, the Octet QK(e) system enables biosensors to be re-racked, for increased workflow flexibility and cost savings.

20 Apr 2010

Positive results from pivotal Phase 3 trials of BENLYSTA in SLE patients

Human Genome Sciences, Inc. and GlaxoSmithKline PLC today announced topline secondary endpoints from BLISS-76, the second of two pivotal Phase 3 trials of BENLYSTA™ (belimumab) in seropositive patients with systemic lupus erythematosus.

20 Apr 2010

TYSABRI drives Biogen Idec's first-quarter revenues of $1.1 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today announced its first quarter 2010 results.

20 Apr 2010

Genentech to pay Seattle Genetics $9.5M for renewing licenses under existing ADC collaboration agreement

Seattle Genetics, Inc. today announced that Genentech, Inc., a wholly owned member of the Roche Group, will pay $9.5 million to renew exclusive licenses to specific targets and extend the research term under the parties' existing antibody-drug conjugate (ADC) collaboration agreement. Under the terms of the agreement, Genentech has rights to use Seattle Genetics' ADC technology with antibodies against targets selected by Genentech.

20 Apr 2010

MUC1 expression indicates progression of pediatric inflammatory bowel disease

Millions of people are afflicted with inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, and 30 percent of new cases occur in childhood. Mucin 1, an epithelial mucin that has been shown to elicit both an immune response and to have altered glycosylation in disease, may be a noninvasive indicator of the progression of these illnesses.

20 Apr 2010

RANKL inhibition may prove effective in treatment of human malignancy, suggests study

Amgen today announced results of a preclinical study demonstrating a positive response to administration of RANK-Fc against mammary tumor formation in mouse models. OPG-Fc and RANK-Fc bind to and block the action of RANKL. These molecules have a comparable mechanism of action to denosumab. The study was presented today in a late-breaking abstract at the American Association for Cancer Research (AACR) 101st Annual Meeting 2010 in Washington, D.C.

20 Apr 2010

Certain genetic mutations lead to Type 1 diabetes: The Scripps Research Institute

Scientists from The Scripps Research Institute have provided an answer to the 40-year-old mystery of how certain genetic mutations lead to Type 1 diabetes. This new molecular understanding could lead to novel therapies for Type 1 diabetes and other autoimmune diseases.

20 Apr 2010

Pre-clinical study results of BiTE antibody technology presented at AACR 2010

Micromet, Inc., a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that results from studies highlighting pre-clinical advances with its proprietary BiTE antibody technology were presented at the American Association for Cancer Research Annual Meeting in Washington, DC.

20 Apr 2010

Study underscores potential for VBL Therapeutics VB-111 as broad-spectrum cancer therapy

VBL Therapeutics today announced positive results from preclinical and Phase 1 studies evaluating the company's lead anti-cancer agent, VB-111 - a first-in-class, targeted biological agent shown to work via dual-action, anti-angiogenic and vascular disruptive mechanism of action - in metastatic cancer. Preclinical data evaluating VB-111 in a comprehensive set of in vivo studies employing the Lewis Lung metastasis mouse model showed the compound to be safe and specific, with a 90% reduction in tumor burden of lung metastases after only one injection.

20 Apr 2010

LifeSpan BioSciences increases number of catalogued, validated IHC-plus antibodies to over 3,500

LifeSpan BioSciences, Inc., a leading provider of antibodies for thousands of researchers worldwide, has increased the number of validated IHC-plus™ antibodies available in its catalog to more than 3,500. With this increase, LifeSpan is well on its way to building the world's largest catalog of well characterized, IHC-validated reagent antibodies. Overall, LifeSpan has a catalog of more than 82,000 antibodies.

20 Apr 2010

Researchers use genistein to improve outlook of pancreatic cancer

Scientists at the Barbara Ann Karmanos Cancer Institute in Detroit today presented data at the American Association for Cancer Research's 101st Annual Meeting 2010 that shows when genistein, a component of soy, is paired with the FDA-approved drug oxaliplatin, pancreatic cancer cells become more sensitive to chemotherapy.

20 Apr 2010

XOMA 052 antibody demonstrates potential for treatment of myeloma patients with elevated IL-6 levels

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that independent researchers presented results showing that XOMA's antibody to interleukin-1 beta (IL-1 beta), XOMA 052, was highly effective in reducing production of a protein that supports the proliferation of cancerous human myeloma cells in vitro.

20 Apr 2010

ThromboGenics microplasmin Phase III program for symptomatic focal VMA meets primary endpoint

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces that its first Phase III trial with microplasmin for the non-surgical treatment of eye disease has met its primary endpoint>Europe, is due to report in the third quarter of 2010.

20 Apr 2010

First case of treating cystic fibrosis and Crohn's disease with infliximab

Cystic fibrosis (CF) is the most common life-threatening autosomal recessive disease in Caucasian children; it has an incidence of 1 case in every 2500 children born alive. CF involves an anomalous function of the exocrine glands, caused by a mutation of a gene (cystic fibrosis transmembrane conductance regulator, CFTR) located on chromosome 7, which codes for a protein involved in ion transport through the cell membrane.

20 Apr 2010

Positive data from NewLink Genetics Phase1/2 study of HyperAcute-Lung cancer immunotherapy

NewLink Genetics Corporation announced today data from a Phase 1/2 study showing that patients with progressive advanced non-small cell lung cancer treated with its HyperAcute®-Lung cancer immunotherapy experienced favorable median survival. The data were presented at the 101st American Association for Cancer Research (AACR) Annual Meeting.

20 Apr 2010

Encorium Group reports 21.4% decrease in fourth-quarter net revenue

Encorium Group, Inc., a full service multinational clinical research organization conducting studies in over 30 countries for many of the world's leading pharmaceutical and biotechnology companies, today announced its financial results for the fourth quarter and year ended December 31, 2009.

20 Apr 2010

NanoImaging Services receives grant to develop methods for characterization of nanoparticle morphology

NanoImaging Services, Inc., announced today that it has received a Small Business Innovation Research (SBIR) grant from the National Institutes of Health through the National Center for Research Resources to develop new methods for quantitative characterization of nanoparticle morphology and aggregation state using transmission electron microscopy. The grant provides approximately $200,000 in research and development funds for a Phase I study.

19 Apr 2010

Immunomedics develops E1-L-thP1 protein complex for targeted delivery of siRNAs to diverse solid cancers

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported the development of a novel protein complex, designated as E1-L-thP1, for targeted delivery of small interfering ribonucleic acids (siRNAs) to diverse solid cancers.

19 Apr 2010

Pivotal preclinical data of YM BioSciences' CYT387 JAK1/2 inhibitor pre-published in Blood

YM BioSciences Inc., announced the pre-publication of pivotal preclinical data for CYT387, the company's highly selective and potent JAK1/2 inhibitor, currently in a Phase I/II trial for myelofibrosis.

19 Apr 2010

Surgery still the only measure to cure RCC

Renal cell carcinoma (RCC) accounts for about 3% of all solid tumours in adults, and worldwide, more than 200.000 new cases and 100.000 deaths result each year from this malignancy.

19 Apr 2010

Antibody News and Research

Further Reading

ForteBio introduces new Octet QK(e) instrumentation system

Positive results from pivotal Phase 3 trials of BENLYSTA in SLE patients

TYSABRI drives Biogen Idec's first-quarter revenues of $1.1 billion

Genentech to pay Seattle Genetics $9.5M for renewing licenses under existing ADC collaboration agreement

MUC1 expression indicates progression of pediatric inflammatory bowel disease

RANKL inhibition may prove effective in treatment of human malignancy, suggests study

Certain genetic mutations lead to Type 1 diabetes: The Scripps Research Institute

Pre-clinical study results of BiTE antibody technology presented at AACR 2010

Study underscores potential for VBL Therapeutics VB-111 as broad-spectrum cancer therapy

LifeSpan BioSciences increases number of catalogued, validated IHC-plus antibodies to over 3,500

Researchers use genistein to improve outlook of pancreatic cancer

XOMA 052 antibody demonstrates potential for treatment of myeloma patients with elevated IL-6 levels

ThromboGenics microplasmin Phase III program for symptomatic focal VMA meets primary endpoint

First case of treating cystic fibrosis and Crohn's disease with infliximab

Positive data from NewLink Genetics Phase1/2 study of HyperAcute-Lung cancer immunotherapy

Encorium Group reports 21.4% decrease in fourth-quarter net revenue

NanoImaging Services receives grant to develop methods for characterization of nanoparticle morphology

Immunomedics develops E1-L-thP1 protein complex for targeted delivery of siRNAs to diverse solid cancers

Pivotal preclinical data of YM BioSciences' CYT387 JAK1/2 inhibitor pre-published in Blood

Surgery still the only measure to cure RCC

Monoclonal Antibody Manufacturing Trends eBook eBook

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest Life Science News